Savara Inc

SVRA · Nasdaq · SIC 2834: Pharmaceutical Preparations
412
SEC Filings

Business Summary

Savara Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for rare respiratory diseases. The company is advancing a product candidate targeting conditions related to pulmonary indications. Savara is conducting clinical trials and pursuing regulatory approval for its pipeline. The company has no currently approved products and relies on third-party manufacturers and clinical research organizations to support its development activities.

Next Earnings

Q2 FY2026 — expected 2026-09-07

Key Facts from Earnings Calls

TypeSubjectDetailQuarter
topic_mentionSVRAdiscussed_in_filing Regulation
topic_mentionSVRAdiscussed_in_filing Regulation
topic_mentionSVRAdiscussed_in_filing Regulation
topic_mentionSVRAdiscussed_in_filing Regulation

Annual Reports (10-K)

FiledPeriodAccessionSourceFull Text
2026-03-132025-12-310001193125-26-105076EDGAR69K words
2025-03-272024-12-310000950170-25-045731EDGAR—
2024-03-072023-12-310000950170-24-027920EDGAR—
2023-03-302022-12-310000950170-23-010967EDGAR—
2022-03-302021-12-310000950170-22-005045EDGAR—
2021-03-102020-12-310001564590-21-011919EDGAR—
2020-03-122019-12-310001564590-20-010465EDGAR—
2019-03-132018-12-310001564590-19-007585EDGAR—
2018-03-142017-12-310001564590-18-005610EDGAR—
2017-03-062016-12-310001564590-17-003487EDGAR—

Quarterly Reports (10-Q)

FiledPeriodAccessionSourceFull Text
2025-11-122025-09-300001193125-25-277525EDGAR20K words
2025-08-132025-06-300000950170-25-107631EDGAR—
2025-05-132025-03-310000950170-25-070283EDGAR—
2024-11-122024-09-300000950170-24-125292EDGAR—
2024-08-122024-06-300000950170-24-095403EDGAR—
2024-05-092024-03-310000950170-24-056954EDGAR—
2023-11-092023-09-300000950170-23-062040EDGAR—
2023-08-102023-06-300000950170-23-041323EDGAR—
2023-05-152023-03-310000950170-23-021981EDGAR—
2022-11-102022-09-300000950170-22-024458EDGAR—
2022-08-112022-06-300000950170-22-016860EDGAR—
2022-05-112022-03-310000950170-22-009344EDGAR—

Recent Current Reports (8-K)

FiledAccessionSourceFull Text
2026-03-130001193125-26-105099EDGAR24K words
2026-01-270001193125-26-023378EDGAR—
2026-01-090001193125-26-008301EDGAR—
2025-10-300001193125-25-258629EDGAR—
2025-10-290001193125-25-256290EDGAR—
2025-09-020001193125-25-193507EDGAR—
2025-06-060001193125-25-137150EDGAR—
2025-05-270001193125-25-126273EDGAR—
2025-03-310001193125-25-067658EDGAR—
2025-03-260001193125-25-064145EDGAR—

412 total filings indexed. 380 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Sector Peers

SXTP — 60 DEGREES PHARMACEUTICALS, INC. ABT — ABBOTT LABORATORIES ABEO — ABEONA THERAPEUTICS INC. ABVC — ABVC BIOPHARMA, INC. ACAD — ACADIA PHARMACEUTICALS INC ACTU — ACTUATE THERAPEUTICS, INC. ADCT — ADC Therapeutics SA ADIL — ADIAL PHARMACEUTICALS, INC.

Tags

rare-respiratory-diseases biopharmaceuticals

Company Identity

CIK0001160308
TickerSVRA
ExchangeNasdaq
SIC2834: Pharmaceutical Preparations
IncorporatedDE

Get More Data

This is the free public profile. For structured JSON with full provenance chain, use the API:

JSON Profile Stock Quote AI Readiness Report
Origin Provenance
page leaf: e679308889a18d36fd658f0919e62521c7f8182338677591855e4aec56139a7b
parent: b5331b6d39bd8d5c2df4ca6e6e16cee3483fad1d30bc6d9b5f4e614f79edb8fb
content hash: 64559ed160e92ca92353721c90c54a97dae41b26ff398054d8863583ffd8d942
signed: 2026-04-13T04:47:40.973Z
sources: 22 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf